{
    "clinical_study": {
        "@rank": "156274", 
        "arm_group": [
            {
                "arm_group_label": "Normal fasting glucose subjects", 
                "arm_group_type": "Experimental", 
                "description": "Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks."
            }, 
            {
                "arm_group_label": "Impaired fasting glucose subjects", 
                "arm_group_type": "Experimental", 
                "description": "Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks."
            }, 
            {
                "arm_group_label": "Diabetic subjects", 
                "arm_group_type": "Experimental", 
                "description": "Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to assess whether pinitol improves hidrocarbonated metabolism\n      parameters, and evaluate its effect on oxidative stress and endothelial function in\n      diabetic, impaired and normal fasting glucose subjects.\n\n      This was a 3-month randomised, controlled-placebo, parallel trial with a three-arm design.\n      Patients were divided into three groups: diabetic (n=40), impaired fasting glucose (n=40) or\n      normal fasting glucose subjects (n=40), receiving 4 g/day of pinitol/placebo."
        }, 
        "brief_title": "Effects of Pinitol on Hidrocarbonated Metabolism Parameters in Diabetic, Impaired and Normal Fasting Glucose Subjects", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes", 
            "Impaired Glucose Tolerance", 
            "Healthy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus, Type 2", 
                "Glucose Intolerance"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Age range of 18-70 years.\n\n          -  Normal fasting glucose subjects were diagnosed as fasting glucose <100 mg/dl and\n             HbA1c <5.7%.\n\n          -  Impaired fasting glucose subjects were diagnosed as fasting glucose between 100 and\n             125 mg/dl and/or HbA1c between 5.7 and 6.4%.\n\n          -  Type 2 Diabetes subjects were diagnosed as basal plasma glucose \u2265 126 mg/dl, at least\n             twice, or glucose levels 2 hours after 75 g oral glucose overload \u2265 200 mg/dl\n             (American Diabetes Association)\n\n        Exclusion criteria:\n\n          -  Morbid obesity\n\n          -  Type 1 diabetes\n\n          -  Heart, liver, thyroid or kidney untreated disease\n\n          -  Neoplasic disease\n\n          -  Hypertriglyceridemia (Triglycerides >400 mg/dl),\n\n          -  Use of drugs that can influence the inflammatory state or insulin sensitivity\n             (NSAIDs, corticosteroids, antiTNF\u03b1) and\n\n          -  Uncontrolled type 2 diabetes (HbA1c \u2265 8%) or with insulin or intestinal\n             disaccharidase inhibitors (acarbose, miglyol,...) treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754792", 
            "org_study_id": "WIL-PIN-2012-02"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normal fasting glucose subjects", 
                "Impaired fasting glucose subjects", 
                "Diabetic subjects"
            ], 
            "description": "Fruit Up\u00ae (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.", 
            "intervention_name": "Pinitol", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "3-O-methyl-D-chiro-inositol"
        }, 
        "intervention_browse": {
            "mesh_term": "Inositol"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 18, 2012", 
        "location": {
            "contact": {
                "email": "hernandez_antmij@gva.es", 
                "last_name": "Antonio Hern\u00e1ndez, Phd, MD", 
                "phone": "34 961622492"
            }, 
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "Spain", 
                    "zip": "46017"
                }, 
                "name": "University Hospital Dr Peset"
            }, 
            "investigator": {
                "last_name": "Antonio Hernandez, Phd, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study on the Influence of Pinitol on Carbohydrate, Lipid and Inflammatory Parameters, Endothelial Function and Oxidative Stress in Diabetic, Impaired and Normal Fasting Glucose Subjects", 
        "overall_official": {
            "affiliation": "Universtiy of Valencia", 
            "last_name": "Antonio Hernandez, MD, Phd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood samples were collected in vacutainer serum separator tubes, after 12- hour overnight fasting, to analyze glucose and insulin concentration at baseline (after a four weeks run-in period of a healthy diet), 6 and 12 weeks after pinitol/placebo administration. Glucose concentrations were measured by means of enzymatic assay in an autoanalyzer. Insulin concentrations were determined by enzyme-linked immunosorbent assay.\nIn a representative group of patients of all groups at time 0 and 10 weeks, a 24 hours glucose levels control were assessed (by means of a continuous glucose monitoring system) for 3 days.\nInsulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR) index (fasting insulin (\u03bcIU/ml) x fasting glucose (mg/dl) /405). Glycosylated hemoglobin (HbA1c) was measured at baseline and 12 weeks in diabetic and impaired fasting glucose subjects.", 
            "measure": "To assess hidrocarbonated metabolism parameters before and after pinitol/placebo administration", 
            "safety_issue": "Yes", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754792"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Valencia", 
            "investigator_full_name": "Antonio Hern\u00e1ndez Mijares", 
            "investigator_title": "PhD, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Total cholesterol and triglycerides were measured by means of enzymatic assays and HDL cholesterol concentrations were recorded using a direct method with an autoanalyzer. LDL cholesterol concentration was calculated using the Friedewald method. Non-HDL cholesterol concentration was obtained by calculating the difference between total and HDL cholesterol. Atherogenic index of plasma was obtained by calculating the logarithm of the ratio of plasma concentration of triglycerides to HDL-cholesterol. Apolipoprotein A-I and B were determined by immunonephelometry. These parameters were measured at baseline, 6 and 12 weeks after pinitol/placebo administration.", 
                "measure": "To evaluate lipid parameters before and after pinitol/placebo administration", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "The evaluation of the inflammatory state was assessed by determination of the concentrations of high sensitive C-reactive protein (hsCRP)(by a latexenhanced immunonephelometric assay) and interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-\u03b1) by xMAP Multiplex technology on the Luminex. These parameters were measured at baseline, 6 and 12 weeks after pinitol/placebo administration.", 
                "measure": "To evaluate inflammatory parameters before and after pinitol/placebo administration", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "E-selectin, ICAM-1 and VCAM-1 were measured by xMAP Multiplex technology on the Luminex at baseline, 6 and 12 weeks after pinitol/placebo administration", 
                "measure": "To evaluate endothelial function before and after pinitol/placebo administration", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Mitochondrial production of reactive oxygen species, levels of calcium, mitochondrial membrane potential and mitochondrial activity were measured at baseline, 6 and 12 weeks after pinitol/placebo administration", 
                "measure": "To evaluate oxidative stress on mitochondrial function before and after pinitol/placebo administration", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "University of Valencia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Valencia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}